Karo Pharma completes the acquisition of Sylphar International NV

Karo Pharma Aktiebolag (“Karo”) today announces that the previously announced acquisition of the Belgian fast-growing digital-first brand company Sylphar International NV (“Sylphar”) for EUR 290m has been successfully completed according to plan. The transaction is expected to contribute positively to Karo’s market position and further enhance Karo’s strong platform for continued growth, particularly in the...